Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?
 

Flexible doses of duloxetine provide greater pain reduction vs placebo for in-patients with Fibromyalgia

Thursday 13 May 2010

CymbaltaMonthly Prescribing Reference reports:

In Patients with Fibromyalgia, Flexible Doses of Duloxetine Provide Greater Pain Reduction vs Placebo

MPR First Report
May 06, 2010

BALTIMORE, Md.—Patients with fibromyalgia reported feeling much better and experienced greater pain reduction with flexible doses of duloxetine [brand name Cymbalta®] (60-120 mg/day) compared with placebo, investigators reported during The American Pain Society's 29th Annual Scientific Meeting. Results from the first fibromyalgia duloxetine trial allowing dose adjustment based on clinical response and tolerability, as is typically done in clinical practice, also found that patients had improvement in sleep, stiffness, and functioning.

Daniel J. Clauw, MD, and colleagues randomized outpatients aged 18 to 65 years with fibromyalgia and ≥4 score on the Brief Pain Inventory (BPI) to either duloxetine (n=263) or placebo (n=267) over 24 weeks. Primary end point was change in symptoms at week 12 using the Patient Global Impression of Improvement (PGI-I). Secondary end points included average pain severity on the BPI, sleep and stiffness (using patient-rated Likert scales), and results from the SF-36, a multi-purpose, short-form health survey.

Duloxetine treatment was initiated at 30 mg/day for 1 week; the dose was then increased to 60 mg/day. Double-blind dose-adjustments were allowed at week 4 (to 90 mg/day) and week 8 (to 120 mg/day or dose reduction). Mean patient global impression of illness severity score at baseline was 3.8 (moderately ill). Increasing the dose of duloxetine in patients who had an inadequate pain response was associated with further pain reduction and suggests that duloxetine 90 mg/day may be an appropriate intermediate dose for some patients.

At end point, patients in the duloxetine group had mean PGI-I scores of 2.8 compared with 3.4 for placebo (P<0.001). Significantly more patients who received duloxetine (57%) reported feeling “much” or “very much” better (PGI-I score ≤2) than those receiving placebo (32.2%; P<0.001). Treatment with duloxetine resulted in significantly greater between-treatment improvement in BPI average pain severity, sleep and stiffness, and all measures on the SF-36 (except role-physical) compared with placebo.

About half of patients received higher doses of duloxetine: 23.6%, 90 mg, and 24.3%, 120 mg. Nausea, headache, constipation, dry mouth, dizziness, diarrhea, and hyperhidrosis occurred in at least 5% of patients treated with duloxetine and significantly more frequently than in those receiving placebo.

The article originally appeared here.

PDF

Cymbalta information from Eli Lilly Australia (PDF, 57KB)

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page